Examiner: MOSELEY II, NELSON B

Tech Center 1600 • Art Units: 1642

This examiner grants 68% of resolved cases

Performance Statistics

67.8%

Allow Rate

+7.8% vs TC avg

659

Total Applications

+41.6%

Interview Lift

1137

Avg Prosecution Days

Based on 621 resolved cases, 2023–2026

6.8%

§101 Eligibility

10.3%

§102 Novelty

34.4%

§103 Obviousness

28.5%

§112 Clarity

App #	Title	Status	Assignee
19539095	PHARMACEUTICAL COMPOSITION COMPRISING A PRMT5 INHIBITOR AND AN EGFR INHIBITOR	Non-Final OA	APEIRON THERAPEUTICS (HONG KONG) LTD.
18182277	ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT AND DETECTION OF CANCER	Non-Final OA	The Regents of the University of California
17327363	TARGETED THERAPY FOR SMALL CELL LUNG CANCER	Final Rejection	The Board of Trustees of the Leland Stanford Junior University

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.